MDWD - Mediwound Ltd

MDWD - Mediwound Ltd

https://www.mediwound.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress - MediWound ( NASDAQ:MDWD )

Benzinga • 1 week, 6 days ago • score: -0.02

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd.

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 3 weeks, 5 days ago • score: 0.10

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. ( Nasdaq: MDWD ) , a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, ...

MediWound Revenue Jumps 43% in Q2

Motley Fool • 1 month ago • score: 0.29

MediWound ( NASDAQ:MDWD ) reported fiscal second quarter 2025 results on Aug. 14, 2025, with revenue rising 43% quarter over quarter to $5.7 million, driven by higher product sales and a favorable mix. The company advanced its Phase III EscharEx VALUE trial, expanded NexoBrid's U.S. presence, and ...

MediWound ( MDWD ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.10

MediWound (MDWD) delivered earnings and revenue surprises of -123.64% and +1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered in Yavne, Israel.

52W High

$22.50

52W Low

$14.14

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.25

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.32

EV/Revenue (<3 favorable)

7.69

P/S (TTM) (<3 favorable)

8.92

P/B (<3 favorable)

8.81

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

17.86%

Institutions (25–75% balanced)

44.70%

Shares Outstanding

10,875,600

Float

7,770,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

19,858,000

Gross Profit (TTM)

3,660,000

EPS (TTM)

-2.60

Profit Margin (>10% good)

-1.42%

Operating Margin (TTM) (higher better)

-1.00%

ROE (TTM) (>15% strong)

-1.49%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.13

Momentum

Bearish momentum

Value

-0.1977

Previous

-0.2631

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025